KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to -$24.8 million.

  • Twist Bioscience's Cash from Operations fell 1580.18% to -$24.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$51.0 million, marking a year-over-year increase of 1844.15%. This contributed to the annual value of -$47.6 million for FY2025, which is 2569.04% up from last year.
  • Per Twist Bioscience's latest filing, its Cash from Operations stood at -$24.8 million for Q4 2025, which was down 1580.18% from -$11.8 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Cash from Operations ranged from a high of -$1.3 million in Q3 2022 and a low of -$54.1 million during Q4 2022
  • For the 5-year period, Twist Bioscience's Cash from Operations averaged around -$24.5 million, with its median value being -$23.2 million (2023).
  • As far as peak fluctuations go, Twist Bioscience's Cash from Operations soared by 9635.95% in 2022, and later tumbled by 153409.63% in 2023.
  • Quarter analysis of 5 years shows Twist Bioscience's Cash from Operations stood at -$46.7 million in 2021, then fell by 15.9% to -$54.1 million in 2022, then soared by 57.51% to -$23.0 million in 2023, then rose by 6.73% to -$21.4 million in 2024, then decreased by 15.8% to -$24.8 million in 2025.
  • Its last three reported values are -$24.8 million in Q4 2025, -$11.8 million for Q3 2025, and -$1.4 million during Q2 2025.